Clinical Research Directory

Inclusion Criteria: * Participant is at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) at the time of signing the Informed Consent Form (ICF). * Participant has primary Stage III or Stage IV disease or first recurrent EC. * Participant must have a documented Mismatch repair (MMR)/Microsatellite Instability (MSI) status. * Participant is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 for Part 1 and an ECOG performance status of 0 or 1 for Part 2. * Participant has adequate organ function. Exclusion Criteria: * Participant has history of or active autoimmune disease that has required systemic treatments within the 2 years prior to screening. * Participant has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known hypersensitivity to carboplatin, paclitaxel or dostarlimab components or excipients. * Participant has received prior therapy with anti-programmed death protein 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-PD-L2 agent. * Participant has known uncontrolled brain or central nervous system (CNS) metastases.